key: cord-1002504-ogiwcz3s
authors: Tan, Elinor; Song, Jialu; Deane, Adam M.; Plummer, Mark P.
title: Global impact of COVID-19 infection requiring admission to the intensive care unit: a systematic review and meta-analysis
date: 2020-10-15
journal: Chest
DOI: 10.1016/j.chest.2020.10.014
sha: 725f532a9767261251739f02c6083b8de63f1a66
doc_id: 1002504
cord_uid: ogiwcz3s

Background The COVID-19 pandemic has placed unprecedented burden on the delivery of intensive care services worldwide. Research question What is the global point estimate of mortality and risk factors for patients admitted to intensive care units (ICUs) with severe COVID-19? Methods In this systematic review and meta-analysis Medline, Embase and the Cochrane library were searched up to 1 August 2020. Pooled prevalence of participant characteristics, clinical features and outcome data were calculated using random effects models. Subgroup analyses were based on geographical distribution, study type, quality assessment, sample size, end date and patient disposition Results Forty-five studies with 16561 patients from 17 countries across four continents were included. Patients with COVID-19 admitted to ICU had a mean age of 62·6 years (95%CI 60.4-64·7). Common comorbidities included hypertension (49·5% (44·9-54·0)) and diabetes (26·6% (22·7-30·8)). Over three-quarters developed Acute Respiratory Distress Syndrome (76·1% (65·7-85·2)). Invasive mechanical ventilation was required in 67.7% (59.1-75.7), vasopressor support in 65·9% (52.4-78.4), renal replacement therapy in 16·9% (12.1-22·2) and extracorporeal membrane oxygenation in 6·4% (4·1-9.1). The duration of ICU and hospital admission was 10·8 days (9·3-18·4) and 19·1 days (16·3-21·9) respectively with in-hospital mortality of 28·1% (23·4-33·0, I2 96%). No significant subgroup effect was observed. Interpretation Critically ill patients with COVID-19 who are admitted to ICU require substantial organ support and prolonged ICU and hospital level care. The pooled estimate of global mortality for severe COVID-19 is <1/3.

Since emerging in December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has placed an unprecedented burden on intensive care units (ICUs) around the world. SARS-CoV-2 is a highly transmissible upper respiratory tract virus that causes coronavirus disease 2019 . A striking feature of COVID-19 is rapidly progressive respiratory failure, which develops in approximately 5% of infected adults 1 .

At the time of writing (28 August 2020) there have been over 24 million confirmed cases of COVID-19 and more than three quarters of a million deaths worldwide 2 . In early case series, mortality rates for critically ill patients with COVID-19 were between 40-61% despite advanced ICU supports [3] [4] [5] . This mortality rate is substantially greater than in previous viral pneumonitis pandemics, such as the 2009 H1N1 influenza pandemic with morality rates between 10-30% 6,7 . Usual provision of ICU level supports has also been strained during the current pandemic by the natural history of severe COVID-19 with reports of protracted ICU lengths of stay 8 .

While COVID-19 is a global pandemic, the burden of disease has not been homogenous and a number of regions that experienced earlier, rapid community spread reported strained or resource limited healthcare systems, which may have contributed to the high mortality 3, 4, 9 . More recent ICU series from regions with lesser COVID-19 population prevalence have reported lower ICU mortality rates of ~15 % 10 . Whilst there is a need to measure the international burden of critical illness 11 there is limited understanding of the global impact and outcomes of COVID-19 infection requiring ICU admission.

The objective of this systematic review and meta-analysis was to provide a contemporary and global assessment of the point estimate of mortality and risk factors for severe disease in patients admitted to an ICU with COVID-19.

This review was performed in accordance with the Meta-analysis of Observational studies in Epidemiology (MOOSE) 12 and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 13 reporting guidelines (e-appendix 1).

Three electronic databases, MEDLINE, EMBASE and the Cochrane Library were searched from inception up until 01 August 2020. Key search terms included 'coronavirus', 'COVID-19', 'SARS-CoV-2' or 'severe acute respiratory syndrome'; and 'intensive care', 'critically ill', 'critical care', 'severe'. Exact terms used are presented in e-appendix 2. In addition, reference lists of relevant studies and review articles were manually searched for potentially eligible studies not captured in the primary search. Corresponding authors were contacted for additional data necessary for a meta-analysis. Two reviewers (ET, JS) independently screened titles and abstracts of all identified studies for eligibility. Any discrepancies were resolved by consensus after discussion with a third reviewer (MP).

The inclusion criteria for studies were: (1) design -randomised controlled trials, nonrandomised controlled trials (case control or controlled cohort), observational studies and case series; (2) study population -adult patients (≥ 18 years) admitted to an intensive care unit (ICU) or high dependency unit (HDU) including studies that compared ICU and non-ICU cohorts; (3) disease -confirmed COVID-19 or SARS-CoV-2; (4) outcome -in-hospital mortality reported. Exclusion criteria were: (1) review articles, opinion articles, case reports;

(2) studies not defining COVID-19 severity or not including baseline physiology data; (3) retracted studies; (4) studies reporting probable COVID-19 only; (5) duplicate patient data (from the same source and capture period) with preference given to sample size and quality for inclusion; (6) studies published in a language other than English.

Two authors (ET, JS) independently extracted predefined data. Data estimated values of the mean and standard deviation were derived by formulas designed by Wan, et al. 14 .

Extracted information included study characteristics (author, geographic location, design, sample size, start and end date), participant characteristics (age, sex, smoking status, body mass index, co-morbidities), presenting symptoms, admission pathology and pulmonary radiology findings (x-ray and computed tomography (CT)), organ system dysfunction, Reports Protocol, as appropriate 15, 16, 17 . Two reviewers independently assessed each study.

Any discrepancies were discussed and resolved by consensus.

The criterion to undertake modelling in the outcome of interest was a minimum of three studies reporting relevant data. The random-effects model (DerSimonian and Laird method) was applied to estimate the pooled prevalence and 95% confidence intervals (CI) 18 . To account for extreme prevalence data, prevalence estimates were transformed using the double arcsine method then back-transformed for ease of interpretation 19 . Publication bias was assessed using the funnel plot with asymmetry ascribed to an LFX index greater than ±1. Statistically significant heterogeneity was assessed as a Cochrane's Q test (p<0.10) and I 2 >75%. Heterogeneity was further explored through subgroup analyses using the following categorical study characteristics; (1) geographical distribution (North America versus Asia versus Europe versus Middle East); (2) quality assessment -risk of bias (high versus low); (3) sample size (>150 versus ≤150 patients); (4) centre type (multi-centre versus single centre);

(5) study type (case series versus retrospective cohort versus case control versus prospective cohort versus prospective cross sectional versus chart review and national audit); (6) study end date (pre-April 2020 versus post-April); (7) patient dispositionproportion censored at study end date (<20% in-hospital at time of publication versus ≥20% in-hospital). Statistical analyses for pooled prevalence were performed using MetaXL, version 5.3 (EpiGear International Pty Ltd). For categorical variables (mortality by gender), pooled odds ratio (OR) and associated 95%CI was calculated using a Mantel-Haenszel (MH) model, and for continuous variables (length of stay), mean differences and associated 95%CI were calculated using an inverse-variance (IV) using Review Manager (RevMan) version 5.3.

A total of 3873 articles were retrieved using the search strategy. After screening by abstract and title, 191 articles were selected for full-text assessment. Forty-five studies met the inclusion criteria and were included in this review and meta-analysis ( Figure 1 ).

The 45 included studies included 16561 patients from 17 countries from December 29, 2019 to July 30, 2020. There were 16 studies from Europe (n=13485) 20 20, 26, 34, 54, 56 , two chart reviews 57, 64 , one cross-sectional study 47 and one national audit 27 . The main characteristics of the included studies are shown in Table 1 and e-appendix 4. Sixty variables were analysed for this meta-analysis ( Table 2) .

Critically ill patients with COVID-19 had a mean age of 62·6 years (95%CI 60·4-64·7), a mean body mass index of 30·1 kg/m 2 (95% CI 28·7-31·4) and over two-thirds were male (65·6% (95%CI 62·7-68·5). Mortality did not differ between gender (OR men vs women 1·20 (95% CI 0·93-1·55; p=0·16) ( Table 2 , e-appendix 5, e-appendix 12). Common comorbidities included hypertension (49·5% (95%CI 44·9-54·0)), diabetes (26·6% (95%CI 22·7-30·8)) and cardiovascular disease (22·2% (95%CI 13·9-31·8)). Nearly a fifth of patients were current smokers (17·4% (95%CI 11·8-23·8)). The most frequent symptoms on presentation were fever (78·9%), dyspnoea (70·0%), cough (68·1%) and anorexia (46·8%). The median time from onset of symptoms to ICU admission was 9·0 days (95%CI 7·9-10·0) ( Table 2 , eappendix 6).

On admission, inflammatory markers were elevated including C-reactive protein 170·0 mg/L (95% CI 113·6-226·3), ferritin 1968·3 µg/ml (95%CI 660·4-3276·1), procalcitonin 1·5 ng/L (95% CI 1·0-2.0) and D-Dimer 3·1 mg/L (95%CI 2·0-4·1). Lactate 1·3 mmol/L (95%CI 1·1-1·6) was not markedly raised. In 10 studies reporting chest-x-ray findings, bilateral infiltrates were seen in 72% (95%CI 48·1-90·7) of patients 40 Over three-quarters of patients were diagnosed with Acute Respiratory Distress Syndrome (ARDS) during their ICU admission (76·1% (95%CI 65·7-85·2)) ( Figure 2 ).

Approximately one-quarter of patients were reported to have: acute kidney injury (AKI) (27·1% (95%CI 20·6-34·2)); shock (25·3% (95%CI 16·7-35·0)); acute cardiac injury (24·2% (95% 13·5-36·7)); arrhythmia (22·7% (95%CI 3·1-50·5)); and/or a thrombotic event (22·6% (95%CI 16·3-29·5)). The pooled initial Sequential Organ Failure Assessment (SOFA) score was 6·3 (95%CI 5·1-7·6) and Acute Physiology and Chronic Health Evaluation (APACHE) II score J o u r n a l P r e -p r o o f was 16·8 (95%CI 14·9-18·8) ( Antimicrobial therapy was administered to 94·6% (95%CI 90·6-97·6) of patients with severe to critical COVID-19 infection. Antiviral therapy use was reported in 18 studies with a pooled prevalence of 74·3% (95%CI 51·9-91·9). Ten studies reported using lopinavir/rotinavir 20, 37, 39, 43, [45] [46] [47] 50, 64, 65 and five studies reported using remdesivir [54] [55] [56] [57] 64 ( Table 2 , e-appendix 9). Glucocorticoid was prescribed to 43·2% (95%CI 24·8-62·5) of patients.

The pooled mean duration of ICU admission was 10·8 days (95%CI 9·3-18·4) and the pooled mean hospital duration of admission was 19·1 days (95%CI 16·3-21·9). The pooled estimate for patients that remained in hospital with uncertain outcomes at the study endpoint was 22·6% (95% CI 16·8-28·9). The pooled estimate for in-hospital mortality was 28·1% (95%CI 23·4-33·0) ( Figure 3 ) and discharge from hospital alive was 43·9% (95%CI 38·9-48·9) albeit with considerable statistical heterogeneity (I 2 96%, p<0·01 and I 2 95%, p<0·01, respectively). The funnel plot of all 45 studies was asymmetrical suggesting possible publication bias ( Table 2 , e-appendix 10-11, e-appendix 13).

Subgroup analyses revealed that mortality did not differ by geographical distribution, study type or quality, sample size, centre type, end of study date, or patient disposition.

There was no evidence of substantial between group heterogeneity of mortality across the pre-specified subgroups. (e-appendix 14).

This systematic review and meta-analysis of 45 studies includes 16561 patients from 17 countries across 4 continents. The main findings are that patients admitted to ICU with COVID-19 required considerable organ support, with point estimates that over threequarters were diagnosed with ARDS and one-quarter recorded as having shock and/or acute kidney injury. Invasive mechanical ventilation and vasopressor support were required in over two-thirds of patients, renal replacement therapy in one-fifth and more than one in J o u r n a l P r e -p r o o f twenty received extracorporeal membrane oxygenation. The in-hospital mortality rate was between 23·4% and 33·0%.

Over 80% of coronavirus cases experience mild to moderate symptoms, approximately 15% have severe disease requiring hospitalisation and around 5% require intensive care support 67, 68 . Previous meta-analyses have examined risk factors for mortality in COVID-19

infections however these studies included a majority of data within a certain region [69] [70] [71] [72] [73] or included patients with COIVD-19 infections but less severe symptoms [74] [75] [76] [77] [78] [79] [80] . To address this limitation, the current systematic review and meta-analysis provides a comprehensive global overview of patient demographic, comorbidities, signs and symptoms, initial laboratory and imaging results, treatment, organ dysfunction and outcomes in adults with severe and critical COVID-19.

Over two-thirds of patients with severe COVID-19 were men, with a mean age of 62·6 years and a mean BMI of 30·1 kg/m 2 confirming previous reports that there is a preponderance to severe disease with male gender, older age and obesity 70, 74 . In keeping with an older, overweight population, we describe a comorbid demographic that progress to severe COVID-19 with half of patients having arterial hypertension and approximately one quarter having diabetes mellitus and cardiovascular disease.

This analysis confirms that across the globe, once admitted to ICU with COVID-19 infection, the duration of admission to ICU and hospital is protracted. The mean ICU length of stay of 10·8 days was approximately double the duration of admission for severe community acquired pneumonia 81 and longer than observed with H1N1 influenza pneumonia 82 . However, the upper 95% confidence interval for in-hospital mortality was only 33·0%. Given that both the duration of admission and the intensity of ICU-level supports have led to enormous strain on critical care provision, particularly in geographic areas that experienced rapid community transmission [83] [84] [85] , this may have contributed to the heterogeneity of mortality data.

These estimates of global mortality for severe COVID-19 (in-hospital mortality rate between 23·4% and 33·0%) may impact interpretation of existing trial data. For example, data from the RECOVERY trial indicated dexamethasone caused a marked reduction in mortality (in-hospital censored at day 28) in patients with COVID-19 who required mechanical ventilation (dexamethasone 29·3% vs. usual care 41·4%) 86 Furthermore, given that global data suggests that less than one-third of patients die once admitted to ICU, the implication of this meta-analysis is that provision of sufficient ICU level service capacity is a global health priority to prevent inequalities in outcomes from this disease.

With 16561 critically ill patients across 17 countries and four continents, this review is the largest and most granular assessment of outcomes of severe COVID-19 to date.

Limitations of this systematic review include the presence of publication bias and that most included studies were case series and retrospective in design. There is a risk of survivor bias with nearly a quarter of patients remaining in hospital. The pooled prevalence for patients discharged alive was only 43·9% (95%CI 38·9 -48·9). Studies varied with the censor date for identifying death. We specified the outcome measure as 'death', 'remained in hospital' and 'discharged alive', and it is possible that all-cause mortality censored at some later landmark (e.g. day 90) may be greater than reported in this meta-analysis. There was considerable statistical heterogeneity found for many results. However, despite exploring the cause of heterogeneity through extensive subgroup analyses, there was no singular cause identified.

Finally, studies were excluded that were not written in English. Whilst the risk of bias from excluding studies not published in English is considered low 87 , it is uncertain how the additional patients would have affected the 95% confidence intervals.

This systematic review provides the most expansive snapshot to date of the international experience of COVID-19 requiring critical care support. Advanced age, male sex, obesity, smoking, hypertension, diabetes and cardiovascular disease are major risk factors for severe COVID-19. Over two-thirds of patients require invasive mechanical ventilation, ~20% require renal replacement therapy and the mean duration of ICU admission was 11 days. There was marked heterogeneity in mortality rate; however, the global mortality rate point estimate for patients with COVID-19 who are admitted to an ICU was 28%. 

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Patients presenting for hospital-based screening for COVID-19: risk of disease, and healthcare access preferences

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Critical care services and 2009 H1N1 influenza in Australia and New Zealand

Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave

Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series

Critical care and the global burden of critical illness in adults

Meta-analysis of Observational Studies in Epidemiology A proposal for reporting

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Estimating the sample mean and standardized deviation from the sample size, median, range and/or interquartile range

Methodological quality and synthesis of case series and case reports

8.2.4. Reaching an overall riskof-bias judgement for a result. 8.2 Overaview of RoB

The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-analysis

Performance of statistical methods for meta-analysis when true study effects are non-normally distributed: A stimulation study

Meta-analysis of prevalence

SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. Anaesthesia Critical Care and Pain Medicine

A cohort of patients with COVID-19 in a major teaching hospital in

Liver injury in critically ill patients with COVID-19: a case series

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy

Obesity, overweight and survival in critically ill patients with SARS-CoV-2 pneumonia: is there an obesity paradox? Preliminary results from Italy

Demographic and clinical features of critically ill patients wiht COVID-19 in Greece: The burden of diabetes and obesity

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

INCNARC. ICNARC report on COVID-19 in critical care 31

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Patients with COVID-19 in 19 ICUs in Wuhan, China: a crosssectional study

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centred, retrospective, observational study

Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou

Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19

Characteristics and Outcomes of 21 Critically Ill Patients with COVID-19 in Washington State

ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease

COVID-19 and cardiac arrhythmias

COVID-19 in critically Ill Patients in the Seattle Region -Case Series

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions

Factors Associated With Intubation and Prolonged Intubation in Hospitalized Patients With COVID-19. Otolaryngology -Head and Neck Surgery (United States)

Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavrius Disease

Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care untis in vancouver, Canada: a case series

Characteristics of Hopitalized Adults with COVID-19 in an Integrated Health Care System in California

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait

Clinical Course and Outcomes of Severe Covid-19: A National Scale Study

Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman

Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait

Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)

Characteristics of and important lessons from coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese centre for Disease Control and Prevention

Risk factors and interventions associated with mortality or survival in adult covid-19 patients admitted to critical care: A systematic review and meta-analysis

Risk Factors for severe disease and efficacy of treatment in patients infected wiht COVID-19: A systematic review, metaanalysis and meta-regression analysis

Risk Factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis

Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature

Comorbidities, clinical signs and symptoms, laboratory findgins, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis

Clinical, laboratory and imaging features of COVID-19: A systematic review and metaanalysis

Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis

Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and metaanalysis

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database

Critical care services and the H1N1 (2009) influenza epidemic in Australia and New Zealand in 2010: the impact of the second winter epidemic

Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response

Critical care crisis and some recommendations during the COVID-19 epidemic in China

Care for Critically Ill Patients With COVID-19

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies

Guarantor: Dr Elinor Tan is the guarantor of the content of this manuscript, including the data and analysis.Author contributions: ET contributed to protocol design, search, data extraction, quality assessment, statistical analysis and writing the first draft of the report. JS contributed to search, data extraction and quality assessment. MP contributed to protocol design, interpretation of data and critical revision of the report. AD contributed to interpretation of data and critical revision of the report. All authors have seen and approved the final version.

J o u r n a l P r e -p r o o f 63 Kuwait Retrospective cohort 42 24/02 -20/4/2020 Good Amit et al (2020) 64 Israel Chart review 156 05/03-27/04/2020 Good Arentz et al (2020) 52 United States Case series 21 20/02-05/03/2020 Fair Auld et al (2020) 53 United States Retrospective cohort 217 06/03-17/04/2020 Poor Barrasa et al (2020) 20 Spain Prospective cohort 48 04/03-24/03/2020 Poor Bhatla et al (2020) 54 United States Prospective cohort 79 06/03-19/05/2020 Good Bhatraju et al (2020) 55 United States Case series 24